How Peptides Signal in the Body

Why this lesson matters

In Lesson 1 we defined what a peptide is. This lesson covers what a peptide does — and that's where most of the confusion in this field actually lives.

If you understand the four concepts in this lesson — receptor binding, half-life, bioavailability, and route of administration — you'll be able to evaluate any peptide protocol you encounter. You'll know why some peptides need daily injections while others work once a week. You'll understand why almost nothing in this field is sold as a pill. And you'll have the foundation for everything that follows in this course.

Let's go.

The lock-and-key model

Here's the core mechanism of how virtually every peptide in this course actually works:

A peptide is a key. Your cells are covered in locks called receptors. When a peptide of the right shape encounters the matching receptor on a cell, it docks into it. That docking triggers a chain of events inside the cell — gene expression changes, proteins get activated or deactivated, signals get sent elsewhere in the body.

The peptide itself doesn't enter the cell in most cases. It just touches the lock from the outside. That's enough to flip the switch.

This is why peptides are so often described as "signaling molecules." They're not building blocks. They're not energy sources. They don't directly modify your DNA. They carry instructions — molecule-to-cell, cell-to-cell — and the magic is in the specificity of which cells get which message.

Why specificity matters: A general drug like aspirin affects many systems at once because it interferes with a broadly-expressed enzyme. A peptide drug, by contrast, can target a specific receptor expressed in a specific tissue at a specific time. That's the promise — and the engineering challenge — of peptide therapeutics.

This is also why peptides tend to have cleaner side-effect profiles than small-molecule drugs. When you bind one specific receptor, you mostly get the effects associated with that receptor. When you affect a broad enzyme, you get effects everywhere that enzyme exists.

Of course, "tend to have" is doing some heavy lifting in that sentence. We'll get into the actual safety considerations in Lesson 5.

Half-life: the most important number you'll never see in marketing

If there's one technical concept worth burning into memory, it's this one.

Half-life is the time it takes for the concentration of a compound in your bloodstream to drop by 50%. If a peptide has a half-life of 6 hours, then 6 hours after injection, half the dose is gone. After 12 hours, three-quarters is gone. After about five half-lives (30 hours in this example), less than 3% remains.

This single number determines almost everything about how a peptide is used in practice.

Consider three examples that illustrate the range:

Ipamorelin has a half-life of roughly 2 hours. To maintain any meaningful effect, it has to be injected once or twice daily.

Sermorelin has a half-life of about 11-12 minutes. Yes, minutes. Its effect is essentially a single pulse — bind, signal, gone. This is actually why it works the way it does for growth hormone release.

Semaglutide has a half-life of about 7 days. This is why Ozempic and Wegovy can be injected weekly instead of daily. The molecule is engineered with structural modifications that protect it from your body's normal clearance mechanisms.

This is the engineering at the heart of modern peptide drug development. Natural peptides have brutally short half-lives — typically minutes — because your body is built to use them as quick bursts of signal and then clear them out fast. Long-lasting peptides have been deliberately modified (with fatty acid chains, PEG groups, or amino acid substitutions) to evade the cleanup crew.

When you read about a peptide's dosing protocol, the dosing frequency is almost always a direct reflection of its half-life. A peptide that needs three injections a day has a short half-life. A peptide injected once a week has been engineered for persistence.

Bioavailability: why most peptides need needles

Here's a problem that drug developers have spent decades trying to solve.

Peptides taken orally have terrible bioavailability — the percentage of a dose that actually reaches your bloodstream in active form. Most peptides, taken as a pill, have an oral bioavailability under 1%.

The reason is straightforward. Your digestive system evolved specifically to break peptides apart. Stomach acid and digestive enzymes don't distinguish between the protein in a steak, the protein in your morning eggs, and a therapeutic peptide. They chop all of it into individual amino acids so your body can absorb the building blocks. By the time anything reaches your bloodstream, the peptide structure — the part that does the signaling — has been destroyed.

This is why almost every peptide in this course is administered by injection. Subcutaneous injection (under the skin) is the most common route. The peptide enters the bloodstream from the injection site, bypassing the digestive system entirely. Bioavailability via subcutaneous injection is typically 80-100% — virtually all of the dose reaches circulation in active form.

There are exceptions, and they're worth knowing:

Oral semaglutide (Rybelsus) is the breakthrough that made oral GLP-1 possible. It's combined with a special absorption enhancer (SNAC) that helps the peptide survive transit through the stomach. Even so, its oral bioavailability is only about 1%. The reason it works is that the molecule is so potent that 1% absorption still produces clinically meaningful effects.

Nasal sprays are an increasingly used route for certain peptides — Selank, Semax, and some forms of oxytocin. The nasal mucosa allows direct absorption into circulation, and for compounds that target the brain, this route can even bypass the blood-brain barrier through the olfactory nerve.

Sublingual (under-the-tongue) forms exist for some peptides, but absorption is highly variable and typically inferior to injection or nasal delivery.

For most of the peptides discussed in this course, the practical reality is: if you want it to work, you inject it. We'll cover the actual mechanics of injection in Lesson 12.

Route of administration: the practical decision tree

Putting the above together, here's how to think about route of administration for any peptide you encounter:

Subcutaneous injection. The default for most therapeutic peptides. Done with a small insulin syringe into the fat layer just under the skin — abdomen, thigh, or back of the arm. High bioavailability. Easy to learn. The default route for BPC-157, TB-500, CJC-1295, Ipamorelin, Sermorelin, GLP-1 drugs, and most of the longevity peptides.

Intramuscular injection. Deeper injection into the muscle. Used when a slower, more sustained absorption profile is desired, or when the peptide is formulated as a longer-acting preparation. Less common in the peptide world than in steroid use.

Intravenous infusion. Direct delivery into a vein. Used in clinical research settings and some specialty clinics for compounds like NAD+ precursors or higher-dose protocols. Highest bioavailability, fastest onset, but requires medical supervision.

Nasal spray. Increasingly common for neuro-targeted peptides. Selank and Semax are almost always administered this way. Bioavailability is moderate (20-30% in most studies) but the route bypasses the blood-brain barrier for centrally-acting compounds.

Oral. Reserved for peptides specifically engineered for oral delivery, or for peptides whose primary site of action is the gut itself. BPC-157 has some preclinical evidence for oral activity targeting GI tissue specifically — though this remains debated.

Topical. Peptides applied to the skin. GHK-Cu (the copper peptide) is the major example here. Used in cosmetic and skincare applications. Bioavailability into systemic circulation is essentially zero — these work locally on the skin tissue.

When evaluating any peptide protocol, the route should match the peptide's known properties. A protocol claiming oral effectiveness for a peptide that's only been studied via injection is a yellow flag — either the protocol creator knows something the published literature doesn't, or they're hoping you don't ask.

Putting it together: a worked example

Let's apply all four concepts to one peptide.

Semaglutide (Ozempic, Wegovy).

• Mechanism: Binds the GLP-1 receptor, which is expressed in the pancreas, gut, and brain. Triggers insulin release, slows stomach emptying, and signals fullness centrally.
• Half-life: ~7 days. This is engineered, not natural — native GLP-1 has a half-life of about 2 minutes. Semaglutide has structural modifications that drastically extend its persistence.
• Bioavailability: Subcutaneous injection delivers ~89% bioavailability. Oral form (Rybelsus) delivers ~1%, made workable only by the potency of the molecule.
• Route: Subcutaneous injection once weekly is the standard. Oral form is available but requires strict timing rules (empty stomach, 30 minutes before food and water).

Every detail of how semaglutide is dosed — once a week, by injection, at a specific concentration — follows directly from its pharmacology. There's no marketing magic here. The protocol is the molecule.

By the end of this course, you'll be able to do this same analysis for any peptide you encounter.